Immix Biopharma, Inc. (IMMX)
Largest Insider Buys in Sector
IMMX Stock Price History Chart
IMMX Stock Performance
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply …
Insider Activity of Immix Biopharma, Inc.
Over the last 12 months, insiders at Immix Biopharma, Inc. have bought $399,139 and sold $0 worth of Immix Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Immix Biopharma, Inc. have bought $406,546 and sold $550 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hsu Jason (director) — $338,059. Morris Gabriel S (CFO) — $21,312. Rachman Ilya M (CEO and Chairman) — $21,168.
The last purchase of 8,100 shares for transaction amount of $18,233 was made by Hsu Jason (director) on 2024‑08‑22.
List of Insider Buy and Sell Transactions, Immix Biopharma, Inc.
| 2024-08-22 | director | 8,100 0.0301% | $2.25 | $18,233 | -16.06% | |||
| 2024-08-21 | director | 15,000 0.0533% | $2.23 | $33,390 | -18.42% | |||
| 2024-08-16 | director | 10,000 0.0379% | $1.86 | $18,600 | 0.00% | |||
| 2024-07-24 | director | 6,000 0.0237% | $2.15 | $12,877 | 0.00% | |||
| 2024-07-18 | director | 3,200 0.0123% | $2.07 | $6,639 | -0.49% | |||
| 2024-06-07 | CEO and Chairman | 2,600 0.0103% | $2.13 | $5,538 | +0.99% | |||
| 2024-06-07 | CFO | 2,500 0.0099% | $2.12 | $5,298 | +0.99% | |||
| 2024-06-04 | CEO and Chairman | 3,300 0.0125% | $1.81 | $5,970 | +12.64% | |||
| 2024-06-04 | CFO | 3,300 0.0125% | $1.81 | $5,973 | +12.64% | |||
| 2024-05-14 | CEO and Chairman | 4,300 0.0166% | $2.25 | $9,660 | -5.45% | |||
| 2024-05-14 | CFO | 4,500 0.0173% | $2.23 | $10,042 | -5.45% | |||
| 2023-12-11 | director | 31,000 0.1596% | $4.67 | $144,894 | -48.91% | |||
| 2023-12-08 | director | 25,000 0.1278% | $4.88 | $122,025 | -51.75% | |||
| 2023-09-15 | director | 7,000 0.04% | $2.49 | $17,396 | +12.36% | |||
| 2023-09-14 | director | 10,000 0.0623% | $2.58 | $25,772 | +17.91% | |||
| 2023-09-14 | director | 10,000 0.0623% | $2.58 | $25,760 | +17.91% | |||
| 2023-09-12 | director | 30,000 0.1874% | $2.83 | $84,864 | +7.55% | |||
| 2023-09-12 | director | 13,000 0.085% | $2.96 | $38,492 | +7.55% | |||
| 2023-09-11 | director | 25,000 0.1563% | $2.89 | $72,280 | +5.28% | |||
| 2023-09-08 | director | 10,000 0.0596% | $2.53 | $25,317 | +14.75% |
Insider Historical Profitability
| Rachman Ilya M | CEO and Chairman | 1136259 4.1393% | $1.59 | 5 | 0 | +36.38% |
| Hsu Jason | director | 845300 3.0794% | $1.59 | 12 | 0 | <0.0001% |
| Morris Gabriel S | CFO | 285834 1.0413% | $1.59 | 5 | 0 | +36.38% |
| Ng Carey | director | 20000 0.0729% | $1.59 | 3 | 0 | <0.0001% |
| Torchilin Vladimir P | Scientific Co-Founder | 905200 3.2976% | $1.59 | 2 | 0 | <0.0001% |